DENSOMERE
LIVE

Serial Number

97040402

Owner

SUSTAINED NANO SYSTEMS, LLC

Attorney

Kathleen A. Costigan

Filing Date

Sep 22, 2021

Add to watchlist:

No watchlists yet
View on USPTO

DENSOMERE Trademark

Serial Number: 97040402

DENSOMERE is a trademark filed by SUSTAINED NANO SYSTEMS, LLC on September 22, 2021. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

SUSTAINED NANO SYSTEMS, LLC

6100 Hollywood Boulevard, Suite 207
Hollywood, FL 33024

Entity Type: 16

Trademark Details

Filing Date

September 22, 2021

Registration Date

Not Registered

Published for Opposition

March 21, 2023

Goods & Services

Drug delivery agents in hypercompressed solid dosage form for implantation under the skin or within the tissue of a bodily organ or within a bodily structure, that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in hypercompressed solid dosage form for injection under the skin or within the tissue of a bodily organ or within a bodily structure, that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in hypercompressed solid dosage form for inhalation or taken orally or placed on the skin for local absorption through the skin, that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in a hypercompressed dosage form in a liquid for implantation under the skin or within the tissue of a bodily organ or within a bodily structure, that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in a hypercompressed dosage form in a liquid for injection under the skin or within the tissue of a bodily organ or within a bodily structure, that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery agents in a hypercompressed dosage form in a liquid for inhalation or taken orally or placed on the skin for local absorption through the skin, that provide controlled release of the active ingredients for a wide variety of pharmaceuticals

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 19, 2025 EXRA
SOU EXTENSION 5 GRANTED
Nov 18, 2025 EX5G
SOU TEAS EXTENSION RECEIVED
Nov 17, 2025 EEXT
SOU EXTENSION 5 FILED
Nov 16, 2025 EXT5
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 17, 2025 EXRA
SOU EXTENSION 4 GRANTED
May 17, 2025 EX4G
SOU EXTENSION 4 FILED
May 16, 2025 EXT4
SOU TEAS EXTENSION RECEIVED
May 16, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 12, 2025 EXRA
SOU EXTENSION 3 GRANTED
Feb 11, 2025 EX3G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 11, 2025 AITU
SOU EXTENSION 3 FILED
Nov 18, 2024 EXT3
SOU TEAS EXTENSION RECEIVED
Nov 18, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
May 17, 2024 EXRA
SOU EXTENSION 2 GRANTED
May 16, 2024 EX2G
SOU EXTENSION 2 FILED
May 16, 2024 EXT2
SOU TEAS EXTENSION RECEIVED
May 16, 2024 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Nov 18, 2023 EXRA
SOU EXTENSION 1 GRANTED
Nov 16, 2023 EX1G
SOU EXTENSION 1 FILED
Nov 16, 2023 EXT1
SOU TEAS EXTENSION RECEIVED
Nov 16, 2023 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
May 16, 2023 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 21, 2023 NPUB
PUBLISHED FOR OPPOSITION
Mar 21, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Mar 1, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 15, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 18, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 17, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 17, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 14, 2022 GNRN
NON-FINAL ACTION E-MAILED
Jul 14, 2022 GNRT
NON-FINAL ACTION WRITTEN
Jul 14, 2022 CNRT
ASSIGNED TO EXAMINER
Jun 23, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 25, 2021 NWOS
NEW APPLICATION ENTERED
Sep 25, 2021 NWAP